Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

159.03 -8.26 (-4.94%)
Streaming Delayed Price Updated: 12:26 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,556,851
Open 167.09
Bid (Size) 158.98 (4)
Ask (Size) 159.08 (2)
Prev. Close 167.29
Today's Range 158.96 - 167.46
52wk Range 130.96 - 182.89
Shares Outstanding N/A
Dividend Yield 3.72%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024
ABBV stock results show that AbbVie beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
AbbVie impresses with Q1 results: EPS beats at $2.31 (-6.1% Y/Y), net revenue exceeds at $12.31 billion (+0.7%). Notable: Immunology sales, Humira vs. biosimilars, oncology gains. 
Via Benzinga

Performance

YTD
-0.49%
-0.49%
1 Month
-11.25%
-11.25%
3 Month
-3.69%
-3.69%
6 Month
+9.52%
+9.52%
1 Year
-1.71%
-1.71%

More News

Read More
AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title
Via Investor's Business Daily
Wall Street Futures Ride High On Microsoft, Alphabet Cheer, But Will Inflation Data Burst The Bubble? Why This Analyst Thinks Bull Run Isn't Over Yet
Via Benzinga
Topics Economy
Exposures Interest Rates
AbbVie's Options Frenzy: What You Need to Know
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today
Via Benzinga
AbbVie's Options Frenzy: What You Need to Know
Via Benzinga
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
Via Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
Via InvestorPlace
Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes
Via InvestorPlace
Buying the Dip in These 3 Undervalued Dividend Stocks
Via The Motley Fool
3 Dividend Kings Down 11% You’ll Regret Not Buying on the Dip
Via InvestorPlace
Is AbbVie a Millionaire Maker?
Via The Motley Fool
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Via Benzinga
Why I Keep Buying This Ultra-High-Yielding ETF for Passive Income
Via The Motley Fool
Topics ETFs
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
Via InvestorPlace
The Bad News Heading Into AbbVie's First-Quarter Earnings Report
Via Investor's Business Daily
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
Via Benzinga
Is Your Botox Real Or Fake? Counterfeit Boxes Circulate For Widely Used Antiwrinkle Treatment, CDC And FDA Investigate Harmful Reactions
Via Benzinga
Exposures Product Safety
Powell And The Great Indecision
Via Talk Markets
Topics Economy
Exposures Economy Interest Rates
Steady Income, Steady Growth: 7 Blue-Chip Dividend Stocks to Buy Now
Via InvestorPlace
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Via Benzinga
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
Via Investor's Business Daily
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
What's Going On AbbVie Stock On Friday?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.